Status:

COMPLETED

Cycled Testosterone Replacement Study

Lead Sponsor:

The University of Texas Medical Branch, Galveston

Conditions:

Hypogonadism

Eligibility:

MALE

60-85 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine whether testosterone (male hormone) therapy is effective if administered in a cyclic fashion (periodic dosing) compared to continuous dosing in men aged 60 to...

Detailed Description

Men and women undergo a progressive reduction in lean muscle mass (sarcopenia) with advancing age regardless of their level of physical activity. A 12-yr longitudinal study in healthy sedentary older ...

Eligibility Criteria

Inclusion

  • Availability of transportation (i.e., subjects must be able to provide their own transportation to UTMB).

Exclusion

  • Medications such as anticoagulants (Coumadin) and glucocorticoids.
  • History of angina that occurs with exertion or at rest.
  • History of myocardial infarction within the last 12 months.
  • Failure to successfully complete an exercise stress test using the Bruce protocol. Subjects that demonstrate ≥ 0.1 mV horizontal or downsloping ST segment depression, a drop in systolic blood pressure of ≥ 10 mm Hg, and/or frequent or repetitive arrhythmias (defined as ≥ 10 PVC/min, or couplets) during the stress test will be excluded.
  • LDL cholesterol above 200 mg/dL.
  • History of prostatic cancer.
  • Elevated prostate specific antigen (PSA) above 4.0 µg/L, or severe benign prostatic hypertrophy (BPH) by history (frequent urination, reduced stream).
  • Serum total testosterone concentrations of greater than 500 ng/dL.
  • Subjects who engage in high intensity, elite training on a regular basis.
  • Major medical illness such as diabetes, chronic obstructive pulmonary disease, or sleep apnea.
  • Recent history of smoking tobacco.
  • Hematocrit greater than 51%.
  • Morbidly obese older men (BMI \> 35).
  • Hypertension: Blood pressure on three consecutive measurements taken at one week intervals that has a systolic pressure ≥ 140 or a diastolic blood pressure ≥ 90. Subjects will be included if they are on two or less blood pressure medications and have a blood pressure below these criteria.
  • History of hepatitis or a 3-fold elevation of liver function tests (Alk phos, ALT, AST).
  • Bone related disorders such as osteoporosis or parathyroid disease.
  • DEXA scans revealing lumbar spine T-scores of less than -2.5.
  • Subjects currently taking anti-bone-resorptive agents such as bisphosphonates, parathyroid hormone, or calcitonin.

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT00957528

Start Date

January 1 2006

End Date

December 1 2008

Last Update

September 10 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Texas Medical Branch

Galveston, Texas, United States, 77555